Latest for Leber Congenital Amaurosis
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Early Check: Expanded Screening in Newborns (RTI International)ClinicalTrials.gov
More about Leber Congenital Amaurosis
These mutations lead to progressive degeneration of retinal photoreceptor cells, particularly cone and rod photoreceptors, resulting in severely compromised vision from the earliest months of life. Patients typically present with severe vision loss, nystagmus (involuntary eye movements), and abnormal pupillary responses. Over time, progressive retinal degeneration leads to complete vision loss in most cases.
Keep reading about Leber Congenital Amaurosis
Clinical examination reveals pale, waxy optic discs and attenuated retinal vessels. Electroretinography shows nonrecordable or severely reduced responses in both photopic and scotopic conditions, a hallmark diagnostic finding. Fundus imaging demonstrates progressive retinal atrophy with variable presentation depending on the genetic subtype.
This genetic heterogeneity has critical implications for treatment, as recent gene therapies are subtype-specific and can only benefit patients carrying mutations in targeted genes. Early genetic testing is therefore essential for prognostication and accessing emerging therapies.
What are the symptoms of Leber Congenital Amaurosis?
These are common symptoms of Leber Congenital Amaurosis, and how strong they are varies from person to person.
- Severe vision loss or blindness from birth or early infancy
- Nystagmus (involuntary eye movements)
- Photophobia (light sensitivity)
- Hyperopia and astigmatism
- Pupillary abnormalities
- Retinal degeneration on imaging
Who gets Leber Congenital Amaurosis?
Leber congenital amaurosis presents from birth or within the first few weeks to months of life. The condition affects males and females equally across all ethnic groups, though certain genetic subtypes and mutations show higher prevalence in specific populations. For example, LCA subtypes caused by mutations in genes like CEP290 and RPE65 are found worldwide, while some rarer subtypes show regional clustering.
Inheritance follows autosomal recessive patterns for the majority of cases, meaning both parents must carry mutations; less commonly autosomal dominant inheritance occurs.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Leber Congenital Amaurosis?
There is currently 1 FDA-approved medication for Leber Congenital Amaurosis.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Leber Congenital Amaurosis treatment
Charity funds and drugmaker programs for Leber Congenital Amaurosis, checked at the source.
No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.
Every program and fund for Leber Congenital Amaurosis, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Leber Congenital Amaurosis
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Leber Congenital Amaurosis resources
Reputable organizations and medical references for learning more about Leber Congenital Amaurosis, including disease registries, foundation resources, and clinical guidelines.